Bladder cancer continues to pose a significant clinical challenge, with accurate imaging and treatment evaluation remaining pivotal in guiding patient management. Recent advances in imaging techniques ...

Using multiparametric MRI (mpMRI) before surgery reduced time to correct treatment by 45 days for patients with muscle invasive bladder cancer. The imaging procedure was successful for over 92% of ...

In patients with suspected muscle-invasive bladder cancer (MIBC), definitive treatment can be expedited by adding multi-parametric magnetic resonance imaging (mpMRI) to flexible cystoscopic biopsy at ...

Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces two "trial in progress" presentations at the 2026 European Association of Urology congress (EAU) in London, UK. These trials investigate ...

Dr. Alexandre Zlotta delivered the State-of-the-art lecture Who really needs surgery after neo-adjuvant chemotherapy? Dr.

Assessing a patient's independence and functional status when selecting and modality of treatment for bladder cancer, notes Michael Leapman, MD, urologic oncologist and associate professor of oncology ...

After decades of limited options, a groundbreaking FDA-approved treatment is opening new doors for people with certain types of bladder cancer. Supported by Johnson & Johnson Bill is a real patient ...

Inlexzo is an intravesical gemcitabine releasing system that is inserted directly into the bladder through a urinary catheter. The Food and Drug Administration (FDA) has approved Inlexzo ™ ...